Trial Profile
Safety and efficacy of low dose sofosbuvir and ribavirin combined with daclatasvir in patients with decompensated HCV cirrhotic patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2016
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 15 Dec 2016 New trial record
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week